Masitinib for the Treatment of Alzheimer’s Disease
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symptoms. Masitinib is a potent and selective phenylaminothiazole-type tyrosine kinase inhibitor which is currently in Phase III studies for the treatment of Alzheimer's disease (AD) with the aim of modifying its evolution and with multiple pharmacological targets such as inhibition of mast cells activity, inhibition of microglia activation, modulation of Aβ and Tau protein signaling pathway and prevention of synaptic damage. Here, we review the preclinical and clinical studies that investigated the administration of masitinib treatment in monotherapy in AD. All research studies revealed positive effects concerning the cognitive functions in AD and generally with good safety and tolerability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Masitinib (28) is a potent and selective tyrosine kinase inhibitor targeting multiple aspects of AD, including inhibition of microglia and mast cell activation, modulation of Aβ and tau protein signaling pathways, and prevention of synaptic damage.475”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [475]
Citations
Cites
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Elmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., & Peterson, J. R. (2011) · Nature Biotechnology · doi:10.1038/nbt.2017 · Cited by 919
Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.-Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.4152-10.2011 · Cited by 654
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Alzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557
Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., Mishina, M., Manabe, T., & Yamamoto, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008085200 · Cited by 466
An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00072 · Cited by 457
Tau interacts with src-family non-receptor tyrosine kinases
Lee, G., Newman, S. T., Gard, D. L., Band, H., & Panchamoorthy, G. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.21.3167 · Cited by 446
Dumitriu, D., Hao, J., Hara, Y., Kaufmann, J., Janssen, W. G. M., Lou, W., Rapp, P. R., & Morrison, J. H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.6410-09.2010 · Cited by 439
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease
Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Do, L. H., Andreadis, A., Van Hoesen, G., & Ksiezak-Reding, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414
Tezuka, T., Umemori, H., Akiyama, T., Nakanishi, S., & Yamamoto, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.435 · Cited by 377
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314
Chin, J., Palop, J. J., Puoliväli, J., Massaro, C., Bien-Ly, N., Gerstein, H., Scearce-Levie, K., Masliah, E., & Mucke, L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2980-05.2005 · Cited by 312
The biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
Mast cells, glia and neuroinflammation: partners in crime?
Skaper, S. D., Facci, L., & Giusti, P. (2014) · Immunology · doi:10.1111/imm.12170 · Cited by 250
Mast cells in neuroinflammation and brain disorders
Hendriksen, E., van Bergeijk, D., Oosting, R. S., & Redegeld, F. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.001 · Cited by 241
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
Barry, A. E., Klyubin, I., Mc Donald, J. M., Mably, A. J., Farrell, M. A., Scott, M., Walsh, D. M., & Rowan, M. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6500-10.2011 · Cited by 237
Microglia and mast cells: two tracks on the road to neuroinflammation
Skaper, S. D., Giusti, P., & Facci, L. (2012) · The FASEB Journal · doi:10.1096/fj.11-197194 · Cited by 235
Williamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227
Xiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
Dendritic spines provide cognitive resilience against Alzheimer's disease
Boros, B. D., Greathouse, K. M., Gentry, E. G., Curtis, K. A., Birchall, E. L., Gearing, M., & Herskowitz, J. H. (2017) · Annals of Neurology · doi:10.1002/ana.25049 · Cited by 198
Regulation of NMDA receptors by the tyrosine kinase Fyn
Trepanier, C. H., Jackson, M. F., & MacDonald, J. F. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08391.x · Cited by 197
Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?
Esposito, Z., Belli, L., Toniolo, S., Sancesario, G., Bianconi, C., & Martorana, A. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12095 · Cited by 196
Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J.-P., et al. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt75 · Cited by 173
Activated microglia drive demyelination via CSF1R signaling
Marzan, D. E., Brügger‐Verdon, V., West, B. L., Liddelow, S., Samanta, J., & Salzer, J. L. (2021) · Glia · doi:10.1002/glia.23980 · Cited by 172
Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease
Seward, M. E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J. N., Li, R., Roberson, E. D., & Bloom, G. S. (2013) · Journal of Cell Science · doi:10.1242/jcs.1125880 · Cited by 169
Skaper, S., Facci, L., & Giusti, P. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130224206 · Cited by 168
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0119-0 · Cited by 165
Suzuki, T., & Okamuranoji, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2662 · Cited by 164
Targeting Fyn Kinase in Alzheimer’s Disease
Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162
Trias, E., Ibarburu, S., Barreto-Núñez, R., Babdor, J., Maciel, T. T., Guillo, M., Gros, L., Dubreuil, P., Díaz-Amarilla, P., Cassina, P., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0620-9 · Cited by 154
Role of Cell Cycle Re-Entry in Neurons: A Common Apoptotic Mechanism of Neuronal Cell Death
Folch, J., Junyent, F., Verdaguer, E., Auladell, C., Pizarro, J. G., Beas‐Zárate, C., Pallàs, M., & Camins, A. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9277-4 · Cited by 154
Self-citationTau protein is essential for stress-induced brain pathology
Lopes, S., Vaz-Silva, J., Pinto, V., Dalla, C., Kokras, N., Bedenk, B., Mack, N., Czisch, M., Almeida, O. F. X., Sousa, N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600953113 · Cited by 147
Haas, L. T., Salazar, S. V., Kostylev, M. A., Um, J. W., Kaufman, A. C., & Strittmatter, S. M. (2016) · Brain · doi:10.1093/brain/awv356 · Cited by 146
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M. C., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 142
Lonskaya, I., Hebron, M. L., Desforges, N. M., Franjie, A., & Moussa, C. E. ‐. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302771 · Cited by 140
Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS
Trias, E., King, P. H., Si, Y., Kwon, Y., Varela, V., Ibarburu, S., Kovacs, M., Moura, I. C., Beckman, J. S., Hermine, O., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.123249 · Cited by 138
The protein tyrosine kinase, fyn, in Alzheimerʼs disease pathology
Shirazi, S. K., & Wood, J. G. (1993) · NeuroReport · doi:10.1097/00001756-199304000-00024 · Cited by 136
Tr‐kit‐induced resumption of the cell cycle in mouse eggs requires activation of a Src‐like kinase
Sette, C., Paronetto, M. P., Barchi, M., Bevilacqua, A., Geremia, R., & Rossi, P. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf553 · Cited by 135
Cesne, A. L., Blay, J., Bui, B., Bouché, O., Adenis, A., Dômont, J., Cioffi, A., Ray-Coquard, I. L., Lassau, N., Bonvalot, S., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.014 · Cited by 128
Fyn-Tau-Amyloid: A Toxic Triad
Haass, C., & Mandelkow�, E. (2010) · Cell · doi:10.1016/j.cell.2010.07.032 · Cited by 117
Mast Cells in Neurodegenerative Disease
Jones, M. K., Nair, A., & Gupta, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00171 · Cited by 108
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Sandhu, J. K., & Kulka, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031093 · Cited by 92
Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?
Marech, I., Patruno, R., Zizzo, N., Gadaleta, C., Introna, M., Zito, A. F., Gadaleta, C. D., & Ranieri, G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.011 · Cited by 90
Boros, B. D., Greathouse, K. M., Gearing, M., & Herskowitz, J. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.003 · Cited by 90
Lonskaya, I., Hebron, M., Selby, S., Turner, R. S., & Moussa, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.070 · Cited by 86
Dendritic Spines: Mediators of Cognitive Resilience in Aging and Alzheimer’s Disease
Walker, C. K., & Herskowitz, J. H. (2021) · The Neuroscientist · doi:10.1177/1073858420945964 · Cited by 86
PAK in Alzheimer disease, Huntington disease and X-linked mental retardation
Ma, Q.-L., Yang, F., Frautschy, S. A., & Cole, G. M. (2012) · Cellular Logistics · doi:10.4161/cl.21602 · Cited by 85
Adenis, A., Blay, J., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Dômont, J., Ray-Coquard, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu237 · Cited by 84
Soria, J., Massard, C., Magné, N., Bader, T., Mansfield, C. D., Blay, J., Bui, B., Moussy, A., Hermine, O., & Armand, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.010 · Cited by 83
Fyn Kinase Controls Tau Aggregation In Vivo
Briner, A., Götz, J., & Polanco, J. C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108045 · Cited by 82
Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS
Trias, E., Ibarburu, S., Barreto-Núñez, R., Varela, V., Moura, I. C., Dubreuil, P., Hermine, O., Beckman, J. S., & Barbeito, L. (2017) · JCI Insight · doi:10.1172/jci.insight.95934 · Cited by 80
Skaper, S. D., Facci, L., Kee, W. J., & Strijbos, P. J. L. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00008.x · Cited by 73
Tang, S. J., Fesharaki-Zadeh, A., Takahashi, H., Nies, S. H., Smith, L. M., Luo, A., Chyung, A., Chiasseu, M., & Strittmatter, S. M. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00976-9 · Cited by 70
Tebib, J., Mariette, X., Bourgeois, P., Flipo, R.-M., Gaudin, P., Le Loët, X., Gineste, P., Guy, L., Mansfield, C. D., Moussy, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2740 · Cited by 68
Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Demetri, G. D. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.018 · Cited by 67
Targeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 63
Harcha, P. A., Vargas, A., Yi, C., Koulakoff, A. A., Giaume, C., & Saez, J. C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3686-14.2015 · Cited by 61
The Role of Mast Cells in Alzheimer’s Disease
Shaik-Dasthagirisaheb, Y. B., & Conti, P. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/61914 · Cited by 57
Son, Y., Jeong, Y. J., Shin, N.-R., Oh, S. J., Nam, K. R., Choi, H.-D., Choi, J. Y., & Lee, H.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155553 · Cited by 51
Li, T., Martin, E., Abada, Y.-S., Boucher, C., Cès, A., Youssef, I., Fenaux, G., Forand, Y., Legrand, A., Nachiket, N., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200466 · Cited by 50
Amyloid β Peptides Trigger CD47-Dependent Mast Cell Secretory and Phagocytic Responses
Niederhoffer, N., Levy, R., Sick, E., Andre, P., Coupin, G., Lombard, Y., & Gies, J.-P. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200224 · Cited by 46
Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice
Babus, L. W., Little, E. M., Keenoy, K. E., Minami, S., Chen, E., Song, J. M., Caviness, J., Koo, S. Y., Pak, D. T. S., Rebeck, G. W., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.07.059 · Cited by 46
Motta, C., Finardi, A., Toniolo, S., Lorenzo, F. D., Scaricamazza, E., Loizzo, S., Mercuri, N. B., Furlan, R., Koch, G., & Martorana, A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191250 · Cited by 44
Novel Targets for Alzheimer's Disease: A View Beyond Amyloid
Ray, W. J., & Buggia-Prevot, V. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 43
Targeting dementias through cancer kinases inhibition
Fagiani, F., Lanni, C., Racchi, M., & Govoni, S. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12044 · Cited by 43
Wang, C., Zhao, C., Liu, W., Huang, X., Deng, Y., Jiang, J., & Li, W. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2019.6460 · Cited by 40
Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor.
Yasunaga, M., Yagi, T., Hanzawa, N., Yasuda, M., Yamanashi, Y., Yamamoto, T., Aizawa, S., Miyauchi, Y., & Nishikawa, S. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.132.1.91 · Cited by 40
Harcha, P. A., Garcés, P., Arredondo, C., Fernández, G. R., Sáez, J. C., & van Zundert, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041924 · Cited by 39
De Sousa, V. L., Araújo, S. B., Antonio, L. M., Silva-Queiroz, M., Colodeti, L. C., Soares, C., Barros-Aragão, F., Mota-Araujo, H. P., Alves, V. S., Coutinho-Silva, R., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.04.001 · Cited by 37
Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
Skaper, S. D. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160829105533 · Cited by 35
Fyn depletion ameliorates tauP301L-induced neuropathology
Liu, G., Fiock, K. L., Levites, Y., Golde, T. E., Hefti, M. M., & Lee, G. S. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00979-6 · Cited by 33
Souter, S., & Lee, G. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611637 · Cited by 28
Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice
Minami, S. S., Clifford, T. G., Hoe, H.-S., Matsuoka, Y., & Rebeck, G. W. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.014 · Cited by 28
Pharmacokinetics of masitinib in cats
BELLAMY, F. D., Bader, T., Moussy, A., & Hermine, O. (2009) · Veterinary Research Communications · doi:10.1007/s11259-009-9231-6 · Cited by 24
Kong, C., Xie, H., Gao, Z., Shao, M., Li, H., Shi, R., Cai, L., Gao, S., Sun, T., & Li, C. (2019) · Virologica Sinica · doi:10.1007/s12250-019-00124-1 · Cited by 18
Masitinib for the treatment of Alzheimer’s disease: clinical and preclinical data
Hermine, O. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.031 · Cited by 3
Aljoundi, A., Agoni, C., Olotu, F. A., & Soliman, M. E. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0354 · Cited by 2
Research works printed but not linked: 6
- 10.1186/s40478-020-00976-9 · DOI · Paper page
- 10.1371/journal.pone.0007258 · DOI · Paper page
- AB Science press release. (2020). https://www.ab-science.com/results-from-phase-2b-3-studyevaluating-masitinib-in-alzheimers-disease/
- 10.1523/JNEUROSCI.4162-03.2004 · DOI · Paper page
- 10.1523/JNEUROSCI.22-01-00010.2002 · DOI · Paper page
- 10.1016/j.cell.2010.06.036 · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023) · Inflammation · doi:10.1007/s10753-022-01721-1 · Cited by 557
“A quadruple, double-blind, placebo study was carried out to evaluate the safety and efficacy of the drug [59].”
BackgroundKumari, S., Dhapola, R., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102098 · Cited by 58
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Zhang, Z., Gan, Q., Han, J., Tao, Q., Qiu, W. Q., & Madri, J. A. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231170041 · Cited by 39
“The src family kinase inhibitor saracatinib (vAZD0530) is the first effort to target Fyn, a member of the Scr family kinase, with a specific inhibitor, which was assessed favorably in a small phase II clinical trial in AD(122) and is currently in a phase III AD clinical trial.(123) It may provide a novel sight for reg…”
Background
Metadata
- Authors
- Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A.
- Affiliations
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Universitat Internacional de Catalunya (ES)
- Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Universitat de Barcelona (ES)
- Venue
- Neurodegenerative Disease Management
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- 11
- Issue
- 4
- Pages
- 263-276
- ISSN
- 1758-2024 (ISSN-L)
- 1758-2032
- OpenAlex
- W3194662903
- Cited by
- 28
- References
- 86
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurodegenerative Disease Management (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- masitinib, Alzheimer's disease, tyrosine kinase inhibitors, mast cell inhibition, microglial activation, amyloid-beta, tau protein, synaptic damage, cognitive function, drug safety and tolerability
- MeSH terms
- Alzheimer Disease, Benzamides, Cognition, Humans, Piperidines, Pyridines, Thiazoles, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.